RA Drug May Help Treat Recalcitrant Eczema
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
The professional-exclusive serum and cream use epidermal growth factor and amino acids to support skin barrier repair, with small clinical studies reporting improvements in redness, hydration, and recovery following aesthetic procedures.